Healthcare

Tesla declines after the electric-vehicle maker's shareholders approve a massive pay package for CEO Elon Musk.

Shares of the medical technology company are headed for their largest same-day percentage increase on record.

Nex-z is the most closely watched drug in Intellia’s development pipeline. The company said in September that it planned to submit the drug for regulatory approval in 2028.

Duolingo declines sharply after its bookings forecast misses estimates, and DoorDash tumbles following an earnings miss.

The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

Shares in AMD rise after the chip maker posts better-than-expected third-quarter earnings and revenue.

Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.

Advisors share steps to take when they realize a client is suffering from cognitive decline.

iRhythm Technologies stock has doubled this year.

The insurer reports better-than-expected quarterly earnings and reaffirms its full-year adjusted earnings guidance.

Both Kimberly Clark and Kenvue are Dividend Aristocrats. Dividends after a merger could well disappoint.

The biotechnology company reported a smaller-than-expected loss in its quarterly figures.

Shares in data analytics software developer Palantir tumble even as the company tops analysts' earnings estimates.

The deal is one of the worst-received major merger deals in recent years.

Zoetis slashes its full-year outlook.

OpenAI strikes cloud computing deal with Amazon, Palantir CEO touts strong third-quarter results, Trump threatens to cut NYC funds, and more news to start your day.

Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

Kenvue shareholders will receive $21.01 a share under terms of the deal.

Vet visits are down, but growing revenue per visit is more than making up for it, the company says.

iPhone maker Apple and cloud-computing and online retailing giant Amazon post better-than-expected earnings.

“The market is entirely too complacent about downside risks,” says one observer. The troubles go beyond a few rough earnings reports.

Revenue attributed to AbbVie’s oncology and aesthetics portfolio declined in the quarter.

The maker of diabetes technology posts better-than-expected revenue but shares are falling.

Alphabet stock rises but Microsoft and Meta fall after the tech giants report quarterly earnings.

Gilead said its new, closely watched HIV drug is now available to 75% of U.S. patients.